Trial Profile
A Phase II Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Efficacy of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor BMS-201038 in Patients With Homozygous Familial Hypercholeterolemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lomitapide (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Aegerion Pharmaceuticals
- 10 Apr 2015 New trial record